Industry News

Highland Therapeutics appoints Dr. Floyd R. Sallee chief medical officer

Centerwatch - Thu, 2014-09-25 10:29
Highland Therapeutics has appointed Dr. Floyd R. Sallee as chief medical officer of Ironshore Pharmaceuticals & Development, Highland's wholly owned principal operating subsidiary.
Categories: Industry News

GlaxoSmithKline appoints Sir Philip Hampton to the board of directors

Centerwatch - Thu, 2014-09-25 10:06
GlaxoSmithKline has announced that Sir Philip Hampton will join the board of the company as non-executive director January 2015 and will become deputy chairman effective April 2015. He will succeed Sir Christopher Gent.
Categories: Industry News

Iodine launches web site, turns real-life experience into data-driven tools

Centerwatch - Thu, 2014-09-25 08:53
Iodine, a provider of online interactive tools, has officially launched at and has begun offering consumers in the U.S. a new way to find and interact with information about their medications. Iodine creates data-driven tools that allow consumers to engage with massive amounts of data in personalized ways, letting any one individual filter data according to demographic information, such as gender and age, to better understand what happens to real people in real life with hundreds of medications.
Categories: Industry News

Bristol-Myers Squibb to build state-of-the-art campus in New Jersey

Centerwatch - Thu, 2014-09-25 08:52
Bristol-Myers Squibb plans to build a 650,000-square-foot office building on company-owned land in Lawrenceville, N.J. Construction is expected to begin in the fall and the new facility is expected to open by the end of 2016.
Categories: Industry News

Baxter, Merrimack Pharmaceuticals ink agreement for MM-398

Centerwatch - Thu, 2014-09-25 08:50
Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as nal-IRI. Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the U.S. and Taiwan, and Merrimack retains commercialization rights in the U.S.; the rights in Taiwan are held separate/news-online/company/EMAly.
Categories: Industry News

Acorda Therapeutics to acquire Civitas Therapeutics

Centerwatch - Thu, 2014-09-25 08:48
Acorda Therapeutics, a biotechnology company based in Ardsley, N.Y., has entered into an agreement to acquire Civitas Therapeutics, a Chelsea, Mass.-based, privately held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a phase III treatment candidate for OFF episodes of Parkinson’s disease (PD). The acquisition also includes rights to Civitas’ proprietary ARCUS pulmonary delivery technology and manufacturing facility with commercial-scale capabilities.
Categories: Industry News

Shire to pay $56.5M to U.S. government

Centerwatch - Thu, 2014-09-25 08:43
Shire has reached a final agreement with the U.S. Attorney’s Office to resolve a civil investigation of its sales and marketing practices for a period ending in 2010 relating to Adderall XR, Vyvanse, Daytrana, Lialda and Pentasa. Shire will pay $56.5 million, plus interest, fees and costs.
Categories: Industry News

Drugs@FDA Data Files

FDA News - Wed, 2014-09-24 15:41
Data files updated through September 24, 2014.
Categories: Industry News

Cytori restructures, cuts third of work force

Centerwatch - Wed, 2014-09-24 09:27
Cytori Therapeutics, a San Diego-based developer of cell therapies based on autologous adipose-derived regenerative cells (ADRCs), plans to restructure its operations and reduce costs.
Categories: Industry News

Atara Biotherapeutics, Memorial Sloan-Kettering Cancer Center ink agreement

Centerwatch - Wed, 2014-09-24 09:25
Atara Biotherapeutics, a California-based, privately held drug development company, has entered into an exclusive option agreement with New York’s Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies, consisting of:
Categories: Industry News

Tekmira joins consortium conducting Ebola virus trials in West Africa

Centerwatch - Wed, 2014-09-24 09:22
Tekmira Pharmaceuticals, a British Columbia-based developer of RNA interference (RNAi) therapeutics, is collaborating with an international consortium to provide an RNAi-based investigational therapeutic for expedited clinical studies in West Africa.
Categories: Industry News

Navidea awarded $1.67M to evaluate Lymphoseek for cervical cancer

Centerwatch - Wed, 2014-09-24 09:20
Navidea Biopharmaceuticals, a Dublin, Ohio developer of precision diagnostics and radiopharmaceutical agents, has received an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.67 million from the National Cancer Institute (NCI), a part of the NIH, to fund evaluation of Lymphoseek (technetium Tc 99m tilmanocept) Injection in women with cervical cancer.
Categories: Industry News

APCER Pharma moves U.S. headquarters to New Jersey

Centerwatch - Wed, 2014-09-24 09:17
APCER Pharma Solutions, a global provider of strategic and outsourced services for clinical safety, pharmacovigilance, medical affairs and regulatory operations, has moved its U.S. headquarters to larger offices within the Princeton Corporate Center in central New Jersey. The new office space more than triples APCER Pharma’s capacity for growth in safety, medical writing and medical information services.
Categories: Industry News

WIRB Copernicus Group acquires ePharmaSolutions

Centerwatch - Wed, 2014-09-24 04:00
WIRB Copernicus Group, after acquiring three IRBs in the past four months, is continuing its spending spree, expanding into a new area with the purchase of ePharmaSolutions (ePS) of Plymouth Meeting, Pa.
Categories: Industry News

Avalon Ventures, GlaxoSmithKline launch two new companies

Centerwatch - Tue, 2014-09-23 05:00
Avalon Ventures has announced the launch of two new companies, Silarus Therapeutics and Thyritope Biosciences, formed through its collaboration with GlaxoSmithKline (GSK) to fund and launch up to 10 early-stage life science companies. Both companies will be located at COI Pharmaceuticals in San Diego, a community established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.
Categories: Industry News

FlowMetric forms new affiliate FlowMetric Diagnostics

Centerwatch - Tue, 2014-09-23 04:00
FlowMetric, a Doyleston, Pa.-based provider of flow cytometry and cell sorting services, has formed a new affiliate company, FlowMetric Diagnostics, for developing advanced companion diagnostics from its flow cytometry platform for use in the global health market.
Categories: Industry News

Minocycline in Patients With Alzheimer's Disease

Alzheimers - Tue, 2014-09-23 01:00
Status: Completed, Condition Summary: Mild Cognitive Impairment; Alzheimer's Disease
Categories: Industry News
Syndicate content